Concomitant use of weight-promoting medications, such as insulin or sulfonylureas, may further blunt the weight loss effects of GLP-1 RAs [45]
Clinical trials with GLP-1 receptor agonists consistently demonstrate significant weight loss, with higher doses (such as semaglutide 2.4 mg weekly) producing approximately 15% average weight loss in adults without diabetes in clinical trials (somewhat less in type 2 diabetes) when combined with lifestyle modification
Anti-inflammatory effects via NF-kB modulation Inflammation and weight loss have a complicated relationship
Renal function has been reported to remain unaffected during oral semaglutide treatment in the PIONEER program [6,7,8,9,10,11,12,13,14,15]
Given the connections affected by cerebellar tDCS, this technology holds promise for treating various motor diseases